Karyopharm Therapeutics (KPTI) Misses Q2 EPS by 15c

Karyopharm Therapeutics (NASDAQ: KPTI) reported Q2 EPS of ($0.92), $0.15 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $150 thousand versus the consensus estimate of $90 thousand.

Financial Outlook

Based on current operating plans, Karyopharm expects that its existing cash and cash equivalents will fund its research and development programs and operations into 2018, including moving the four later-stage clinical studies to their next data inflection points. Karyopharm expects to end 2015 with greater than $200 million in cash, cash equivalents and investments.

For earnings history and earnings-related data on Karyopharm Therapeutics (KPTI) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• UBS Reiterates Neutral Rating on Intuit (INTU), Says Investor Day Not 'Sentiment-Changing'